Projects per year
Personal profile
Headline
ASSISTANT PROFESSOR (PENDING) | Medicine, Hematology and Medical Oncology
Fingerprint
Dive into the research topics where Suchitra Sundaram is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 2 Active
-
A unified citywide dashboard for allocation and scheduling dialysis for COVID-19 patients on maintenance hemodialysis
On Behalf Of The 'project Victory' Consortium, 1 May 2022, In: Indian Journal of Nephrology. 32, 3, p. 197-205 9 p.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
CLL-120 Pirtobrutinib, A Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study
Coombs, C. C., Pagel, J. M., Shah, N. N., Lamanna, N., Munir, T., Lech-Maranda, E., Eyre, T. A., Woyach, J. A., Wierda, W. G., Cheah, C. Y., Cohen, J. B., Roeker, L. E., Patel, M. R., Fakhri, B., Barve, M. A., Tam, C. S., Lewis, D., Gerson, J. N., Alencar, A., Ujjani, C., & 17 others, Oct 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, p. S268-S269Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study
Cohen, J. B., Shah, N. N., Alencar, A. J., Gerson, J. N., Patel, M. R., Fakhri, B., Jurczak, W., Tan, X. N., Lewis, K. L., Fenske, T., Coombs, C. C., Flinn, I. W., Lewis, D. J., Gouill, S. L., Palomba, M. L., Woyach, J. A., Pagel, J. M., Lamanna, N., Barve, M. A., Ghia, P., & 15 others, Oct 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, p. S394-S395Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
Ofatumumab plus HyperCVAD/HD-MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 study
Torka, P., Akhtar, O. S., Reddy, N. M., Baysal, B. E., Kader, A., Groman, A., Nichols, J., Mavis, C., Tario, J. D., Block, A. M. W., Sait, S. N. J., Ghione, P., Sundaram, S., Przespolewski, E. R., Mohr, A., Lund, I., Kostrewa, J., McWhite, K., DeMarco, J., Johnson, M., & 6 others, 15 Apr 2022, In: Cancer. 128, 8, p. 1595-1604 10 p.Research output: Contribution to journal › Article › peer-review
-
Burkitt Lymphoma International Prognostic Index
The Burkitt Lymphoma International Prognostic Index Consortium, 1 Apr 2021, In: Journal of Clinical Oncology. 39, 10, p. 1129-1138 10 p.Research output: Contribution to journal › Article › peer-review
14 Scopus citations
Press / Media
-
Venetoclax Regimens for 'Fit' CLL Yield High Undetectable MRD Rates
13/12/21
1 item of Media coverage
Press/Media
-